These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2885674)

  • 1. Efficacy of recombinant DNA Plasmodium falciparum sporozoite vaccine?
    Grove DI
    Lancet; 1987 Jul; 2(8552):220. PubMed ID: 2885674
    [No Abstract]   [Full Text] [Related]  

  • 2. The real difficulties for malaria sporozoite vaccine development: nonresponsiveness and antigenic variation.
    Good MF; Kumar S; Miller LH
    Immunol Today; 1988 Nov; 9(11):351-5. PubMed ID: 3076406
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine.
    Ballou WR; Hoffman SL; Sherwood JA; Hollingdale MR; Neva FA; Hockmeyer WT; Gordon DM; Schneider I; Wirtz RA; Young JF
    Lancet; 1987 Jun; 1(8545):1277-81. PubMed ID: 2884410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
    Mehrizi AA; Zakeri S; Rafati S; Salmanian AH; Djadid ND
    Parasite Immunol; 2011 Nov; 33(11):594-608. PubMed ID: 21883290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte responsiveness to a candidate malaria sporozoite vaccine (R32tet32) of individuals with naturally acquired Plasmodium falciparum malaria.
    Webster HK; Ho M; Looareesuwan S; Pavanand K; Wattanagoon Y; Warrell DA; Hockmeyer WT
    Am J Trop Med Hyg; 1988 Jan; 38(1):37-41. PubMed ID: 3277463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.
    Wizel B; Houghten RA; Parker KC; Coligan JE; Church P; Gordon DM; Ballou WR; Hoffman SL
    J Exp Med; 1995 Nov; 182(5):1435-45. PubMed ID: 7595214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of protective immunity against experimental infection with malaria using synthetic peptides.
    Patarroyo ME; Romero P; Torres ML; Clavijo P; Moreno A; Martínez A; Rodríguez R; Guzman F; Cabezas E
    Nature; 1987 Aug 13-19; 328(6131):629-32. PubMed ID: 3302727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sporozoite immunity and vaccine development.
    Hockmeyer WT; Ballou WR
    Prog Allergy; 1988; 41():1-14. PubMed ID: 3043419
    [No Abstract]   [Full Text] [Related]  

  • 9. Malaria vaccines. Are they approaching reality?
    Perlmann P
    Nature; 1987 Jul 16-22; 328(6127):205-6. PubMed ID: 3299105
    [No Abstract]   [Full Text] [Related]  

  • 10. Towards a malaria vaccine: what is in sight?
    del Giudice G
    Allergol Immunopathol (Madr); 1991; 19(3):129-35. PubMed ID: 1799171
    [No Abstract]   [Full Text] [Related]  

  • 11. [NANP]19-5.1. A malaria vaccine field trial in Nigerian children.
    Reber-Liske R; Salako LA; Matile H; Sowunmi A; Stürchler D
    Trop Geogr Med; 1995; 47(2):61-3. PubMed ID: 8592764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malaria vaccine development using synthetic peptides as a technical platform.
    Corradin G; Céspedes N; Verdini A; Kajava AV; Arévalo-Herrera M; Herrera S
    Adv Immunol; 2012; 114():107-49. PubMed ID: 22449780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The case for a subunit vaccine against malaria.
    Anders RF
    Trends Parasitol; 2011 Aug; 27(8):330-4. PubMed ID: 21592861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines.
    Del Giudice G; Cooper JA; Merino J; Verdini AS; Pessi A; Togna AR; Engers HD; Corradin G; Lambert PH
    J Immunol; 1986 Nov; 137(9):2952-5. PubMed ID: 3531341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Malaria vaccine research].
    Sellioğlu B
    Mikrobiyol Bul; 1986 Jan; 20(1):37-41. PubMed ID: 3523172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunologic prevention of malaria].
    Wagner WH
    Med Monatsschr Pharm; 1990 Jul; 13(7):209-15. PubMed ID: 1695990
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.
    Herrington DA; Clyde DF; Losonsky G; Cortesia M; Murphy JR; Davis J; Baqar S; Felix AM; Heimer EP; Gillessen D
    Nature; 1987 Jul 16-22; 328(6127):257-9. PubMed ID: 2439920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteosome-hydrophobic 'foot' malaria peptide vaccines for Plasmodium falciparum and P. vivax.
    Lowell GH; Ballou WR; Smith LF; Zollinger WD; Hockmeyer WT
    Trans R Soc Trop Med Hyg; 1989; 83 Suppl():101-2. PubMed ID: 2696152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens.
    Quakyi IA; Otoo LN; Pombo D; Sugars LY; Menon A; De Groot AS; Johnson A; Alling D; Miller LH; Good MF
    Am J Trop Med Hyg; 1989 Aug; 41(2):125-34. PubMed ID: 2672834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of cell-mediated immune responses directed against P. falciparum sporozoite peptide vaccine by immunomodulators.
    Russo DM; Sundy JS; Maguire HC; Weidanz WP
    Adv Exp Med Biol; 1989; 251():203-7. PubMed ID: 2692427
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.